Novavax (NASDAQ:NVAX) acquire shares Four% Vaccine maker has been granted emergency use listing by the World Health Organization for its latest protein-based COVID-19 vaccine, Nuvaxovid XBB.1.5 COVID-19 Vaccine (NVX-CoV2601). The announcement was made before the market on Tuesday.
“Updated protein-based WHO emergency use list Non-mRNA COVID-19 vaccines enable rapid regulatory approval in 194 Member States and UN procurement agencies such as UNICEF, thereby supporting equitable access to our vaccines around the world ” said John Jacobs, President and CEO.
This grant supports non-compliance demonstrating that Novavax’s (NVAX) COVID-19 vaccine elicited functional immune responses against XBB.1.5, XBB.1.16, and XBB.2.3 variants. Based on clinical data.
Additional non-clinical data show that the vaccine induces neutralizing antibody responses against subvariants BA.2.86, EG.5.1, FL.1.5.1, and XBB.1.16.6, as well as CD4+ multifunctional cell (T cell) responses against EG.5.1. demonstrated that it induced a response. and XBB.1.16.6.
The latest coronavirus vaccines have been authorized in the United States and the European Union, and are under review in other markets.